Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival

This article was originally published in The Pink Sheet Daily

Executive Summary

While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.

You may also be interested in...



Alimta To Replace Taxotere As Standard For Non-Small Cell Lung Cancer – Lilly

Lilly expects its non-small cell lung cancer therapy Alimta (pemetrexed) to replace Taxotere (docetaxel) as the standard of care in the second-line setting, Exec VP-Pharmaceutical Operations John Lechleiter said Jan. 11 at the J.P. Morgan health care conference in San Francisco

Alimta To Replace Taxotere As Standard For Non-Small Cell Lung Cancer – Lilly

Lilly expects its non-small cell lung cancer therapy Alimta (pemetrexed) to replace Taxotere (docetaxel) as the standard of care in the second-line setting, Exec VP-Pharmaceutical Operations John Lechleiter said Jan. 11 at the J.P. Morgan health care conference in San Francisco

Aventis' Taxotere Gets Breast Cancer Claim With 25.7% Reduction In Relapse Risk

A 1,491-patient study shows overall survival was longer with the docetaxel arm over the TAC and FAC regimens. The approval is the second new indication for Taxotere in the last three months.

Related Content

Topics

UsernamePublicRestriction

Register

PS060334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel